Ignite Creation Date:
2024-05-05 @ 5:18 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00426816
Status:
COMPLETED
Last Update Posted:
2012-08-13
First Post:
2007-01-23
Brief Title:
To Evaluate The Effects Of SB-649868 10 30 Mg And 60 Mg On Subjects With Primary Insomnia
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Multi-centre Randomized Double-blind Placebo-controlled Cross-over Study to Evaluate the Effects of SB-649868 10 30 mg and 60 mg on Sleep Continuity PSG Sleep Recordings Subjective Sleep Assessment and Daytime Cognitive Function in Subjects With Primary Insomnia
Status:
COMPLETED
Status Verified Date:
2012-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study to evaluate the effects of SB-649868 10 30 mg and 60 mg on sleep continuity PSG sleep recordings subjective sleep assessment and daytime cognitive function in subjects with primary insomnia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None